ClearPoint Neuro (CLPT) CEO sells 61,843 shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported an exercise-and-sell transaction in company stock. He exercised stock options for 60,000 shares of common stock at $2.50 per share and sold 60,000 shares held directly at a weighted average price of $17.79 per share. In a separate indirect transaction, the Joseph M. Burnett Trust dated 10/20/2022, for which he serves as trustee, sold 1,843 shares at a weighted average price of $17.94 per share. Following these transactions, Burnett held 116,842 shares directly and 191,388 shares indirectly through the trust, and the option award referenced in the filing covered 270,000 shares after the exercise. The filing notes that the option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 61,843 shares ($1,100,463)
Net Sell
4 txns
Insider
BURNETT JOSEPH
Role
CEO and President
Sold
61,843 shs ($1.10M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (right to buy) | 60,000 | $0.00 | -- |
| Exercise | Common Stock | 60,000 | $2.50 | $150K |
| Sale | Common Stock | 60,000 | $17.79 | $1.07M |
| Sale | Common Stock | 1,843 | $17.94 | $33K |
Holdings After Transaction:
Stock Options (right to buy) — 270,000 shares (Direct, null);
Common Stock — 176,842 shares (Direct, null);
Common Stock — 191,388 shares (Indirect, See Footnote)
Footnotes (1)
- The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.35 to $18.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.75 to $18.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017.
Key Figures
Direct shares sold: 60,000 shares
Indirect shares sold via trust: 1,843 shares
Options exercised: 60,000 shares at $2.50
+5 more
8 metrics
Direct shares sold
60,000 shares
Common Stock sold at $17.79 weighted average on June 17, 2026
Indirect shares sold via trust
1,843 shares
Common Stock sold at $17.94 weighted average on June 17, 2026
Options exercised
60,000 shares at $2.50
Stock options (right to buy) exercised into Common Stock
Direct holdings after trade
116,842 shares
Common Stock held directly after June 17, 2026 transactions
Indirect holdings after trade
191,388 shares
Common Stock held by Joseph M. Burnett Trust after transactions
Option position after exercise
270,000 options
Stock Options (right to buy) total following June 17, 2026 exercise
Sale price range (trust)
$17.35–$18.15
Price range for indirectly held shares sold; weighted avg $17.94
Sale price range (direct)
$17.75–$18.08
Price range for directly held shares sold; weighted avg $17.79
Key Terms
Rule 10b5-1, weighted average sales price per share, Stock Options (right to buy), trading plan, +1 more
5 terms
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted ... in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Stock Options (right to buy) financial
"Stock Options (right to buy) ... underlying security title Common Stock"
trading plan regulatory
"were made pursuant to a written trading plan adopted by the Reporting Person"
A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.
trustee other
"owned directly by the Joseph M. Burnett Trust ... and indirectly by Joseph M. Burnett as trustee"
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
FAQ
What insider transaction did ClearPoint Neuro (CLPT) report for CEO Joseph Burnett?
ClearPoint Neuro reported that CEO Joseph Burnett exercised options and sold shares. He exercised 60,000 stock options at $2.50 per share and sold 60,000 directly held shares plus 1,843 shares held through a trust on June 17, 2026.
Were Joseph Burnett’s ClearPoint Neuro (CLPT) stock sales made under a Rule 10b5-1 plan?
Yes, the option exercise and related sales were executed under a Rule 10b5-1 plan. The filing states they were made pursuant to a written trading plan Burnett adopted on June 11, 2025, which pre-arranged the transactions.
What stock option activity did ClearPoint Neuro (CLPT) disclose for its CEO?
The CEO exercised stock options for 60,000 ClearPoint Neuro shares at $2.50 per share. These options relate to an award granted November 7, 2017, with vesting over three years, and the option position covered 270,000 shares following the exercise.